Contrast-induced nephropathy in coronary angiography patients when using Ioversol and Iomeprol : a meta-analysis

Abstract

Ioversol and Iomeprol are radiological contrast media commonly used interchangeably in many South African imaging facilities for coronary angiography. Despite differences in chemical composition, they are presumed to have similar renal safety profiles. However, no studies directly compare the renal safety of these two contrast media for coronary angiography in a predominantly healthy population. A systematic review was performed to establish which contrast medium is safer. Articles were sourced from Medline, CINAHL, Scopus, Science Direct, and PubMed Clinical Queries databases. Eligible studies were peer-reviewed articles of coronary angiography examinations carried out on a healthy adult population, where Ioversol or Iomeprol or both were administered, with contrast-induced nephropathy as an end-point. Six articles with a total population of 2431 patients were selected. The Cochrane Risk of Bias Tool was used in evaluating included articles. Pooling studies using the random effects model did not show a statistically significant reduction in contrast-induced nephropathy when Iomeprol was administered (Risk ratio 1.14, 95% confidence interval 0.797-1.643, p = 0.466). Moderate heterogeneity (I2=54.21%) across the studies was observed. Study limitations included potential bias during data extraction because this was performed by a single reviewer, and language restrictions to include only English titles. Iomeprol may be better for use in the clinical setting because of more a predictable renal safety profile.